Wide Ranks

LNTH

Lantheus Holdings, Inc.

90.27

Top Statistics
Market Cap 6 B Forward PE 13.34 Revenue Growth 18.40 %
Current Ratio 1.65 Trailing PE 15.00 Earnings Growth -4.80 %
Profit Margins 28.57 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 11.00 Enterprise / Revenue 4.03 Price To Sales Trailing12 Months 4.19
Profitability
Profit Margins 28.57 % Operating Margins 35.31 %
Balance Sheet
Total Cash 866 M Total Cash Per Share 12.46 Total Debt 621 M
Total Debt To Equity 52.67 Current Ratio 1.65 Book Value Per Share 16.97
All Measures
Short Ratio 357.00 % Message Board Id finmb_8285048 Fax 978 671 8860
Shares Short Prior Month 4 M Return On Equity 0.4553 City Bedford
Uuid e854c3fb-8328-3f4c-9161-58b3c91379f7 Previous Close 89.53 First Trade Date Epoch Utc 1 B
Book Value 16.97 Beta 0.5120 Total Debt 621 M
Volume 959872 Price To Book 5.32 Fifty Two Week Low 50.20
Total Cash Per Share 12.46 Total Revenue 1 B Shares Short Previous Month Date 1 B
Target Median Price 135.00 Max Age 86400 Recommendation Mean 1.33
Sand P52 Week Change 0.3133 Operating Margins 35.31 % Target Mean Price 134.00
Net Income To Common 427 M Short Percent Of Float 0.0845 Implied Shares Outstanding 69 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 866 M Next Fiscal Year End 1 B
Revenue Per Share 21.69 Held Percent Insiders 0.0247 Ebitda Margins 36.62 %
Trailing PE 15.00 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 89.53 Target Low Price 110.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 102.12 Open 90.40 Free Cashflow 246 M
State MA Dividend Yield 0.00 % Return On Assets 0.1700
Time Zone Short Name EST Trailing Eps 6.02 Day Low 89.08
Address1 201 Burlington Road Shares Outstanding 69 M Price Hint 2
Target High Price 166.00 Website https://www.lantheus.com 52 Week Change 0.2604
Average Volume 950593 Earnings Quarterly Growth -0.70 % Forward Eps 6.93
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 152.50 %
Is_sp_500 False Regular Market Day High 91.15 Profit Margins 28.57 %
Debt To Equity 52.67 Fifty Two Week High 126.89 Day High 91.15
Shares Short 4 M Regular Market Open 90.40 Industry Key drug-manufacturers-specialty-generic
Earnings Growth -4.80 % Enterprise To Revenue 4.03 Revenue Growth 18.40 %
Shares Percent Shares Out 0.0641 Operating Cashflow 499 M Currency USD
Time Zone Full Name America/New_York Market Cap 6 B Is_nasdaq_100 False
Zip 01730 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Lantheus Holdings, Inc. Regular Market Day Low 89.08 Held Percent Institutions 1.07
Current Price 90.27 Address2 South Building Enterprise To Ebitda 11.00
Financial Currency USD Current Ratio 1.65 Gross Margins 64.38 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 11 Country United States
Float Shares 68 M Two Hundred Day Average 87.02 Enterprise Value 6 B
Price To Sales Trailing12 Months 4.19 Forward PE 13.34 Regular Market Volume 959872
Ebitda 548 M Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.

In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;.

It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.

The company was founded in 1956 and is based in Bedford, Massachusetts.